Surprise Me!
Biocon Eyes First Mover Advantage With Launch Of Neulasta Biosimilar
2022-02-25
2
Dailymotion
Please enable JavaScript to view the
comments powered by Disqus.
Related Videos
Biocon Rallies On FDA's Letter On Mylan's Biosimilar
Biocon Outlook On The Biosimilar Sales | NDTV Profit
Kiran Mazumdar Shaw of Biocon on biosimilar & business outlook
Biocon Jumps On FDA's Letter On Mylan's Biosimilar
Biocon Says New Biosimilars To Drive Growth For Next 5 Years
Biocon Plays The Biosimilars Card
Biocon & Mylan Launch Cancer Drug In U.S.
Growth momentum to continue in Q2, H2 due to trastuzumab launch, says Biocon
Kiran Mazumdar of Biocon on launch of insulin glargine
Fidel Castro's Keywords
Buy Now on CodeCanyon
